DASON COVID-19 Weekly Treatment Literature Update 11/6/2020
Prepared by: Angelina Davis, PharmD, MS, April Dyer, PharmD, MBA, MSCR, Elizabeth Dodds Ashley, PharmD, MHS, Melissa Johnson, PharmD, MHS, S. Shaefer Spires, MD, Travis Jones, PharmD

The following summarizes key literature pertaining to treatment of COVID-19 during the past week. *Note: some of the data discussed below may be in pre-print form that has not yet been peer-reviewed. We have noted some discrepancies in some of this data, and final printed versions may ultimately differ from what is shown here. We will update as soon as possible; caution is advised when interpreting this literature.

NIH Guideline Updates
The NIH Treatment Guidelines were updated on 11/3.

Key Updates to the Guidelines
Remdesivir
On October 22, 2020, the Food and Drug Administration (FDA) approved remdesivir for the treatment of hospitalized patients with COVID-19. Several Guidelines sections related to remdesivir (Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19, Remdesivir, Remdesivir: Selected Clinical Data, and Table 2) have been updated. The updated information includes:

- The addition of key information from the FDA product label and updates that correspond to changes to the remdesivir Emergency Use Authorization;
- The addition of a study description in the Remdesivir: Selected Clinical Data section; and
- Updates to remdesivir-related considerations in pregnancy.

The Panel’s recommendations for the use of remdesivir (with or without corticosteroids) based on disease severity and the rationale for each recommendation have been moved to the Therapeutic Management of Patients with COVID-19 section.

A number of sections of the Guidelines have been updated to remove statements indicating that no drugs have been approved by the FDA for the treatment of COVID-19.

Corticosteroids
This section has been updated to include summaries for a number of recently published studies on the use of corticosteroids for the treatment of patients with COVID-19. The Panel’s recommendations for the use of corticosteroids (with or without remdesivir) based on disease severity and the rationale for each recommendation have been moved to the Therapeutic Management of Patients with COVID-19 section.

Other Updates to the Guidelines
Testing for SARS-CoV-2 Infection
This section has been updated with additional information on who should be tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the diagnostic tests that are currently under investigation.
**Vitamin C**
This section has been updated with new clinical trial data on the use of vitamin C and thiamine (with or without hydrocortisone) in patients with severe pneumonia, sepsis, or septic shock.

The guidelines can be found at this link: https://www.covid19treatmentguidelines.nih.gov/whats-new/

**Therapeutic/Regulatory Information**

**New Literature This Week**
There have been no major COVID-related publications this week that would alter clinical practice.

**Treatment Summary Tables**

*NIH Treatment Guidelines Summary:*

The remdesivir summary table with the information of published studies to date can be found at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-remdesivir-covid-19

The hydroxychloroquine summary table is available at this link:

The tocilizumab summary table with the information of published studies to date can be found at this link

The convalescent plasma summary table is available at this link:

All FAQs available here: https://dason.medicine.duke.edu/covid-19-novel-coronavirus-resources